BR112017025739A2 - composição farmacêutica oral de isotretinoína que tem biodisponibilidade aumentada, processo para preparar a mesma e método de tratamento - Google Patents

composição farmacêutica oral de isotretinoína que tem biodisponibilidade aumentada, processo para preparar a mesma e método de tratamento

Info

Publication number
BR112017025739A2
BR112017025739A2 BR112017025739A BR112017025739A BR112017025739A2 BR 112017025739 A2 BR112017025739 A2 BR 112017025739A2 BR 112017025739 A BR112017025739 A BR 112017025739A BR 112017025739 A BR112017025739 A BR 112017025739A BR 112017025739 A2 BR112017025739 A2 BR 112017025739A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
oral pharmaceutical
preparing
treatment
increased bioavailability
Prior art date
Application number
BR112017025739A
Other languages
English (en)
Inventor
Prabhakar Amrutkar Pankaj
Kochhar Ravi
Deshmukh Subodh
Madan Sumit
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of BR112017025739A2 publication Critical patent/BR112017025739A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/006—Pressing and sintering powders, granules or fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
    • A61J3/074—Filling capsules; Related operations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00—Other particular articles
    • B29L2031/753—Medical equipment; Accessories therefor

Abstract

a presente invenção fornece uma composição farmacêutica oral de isotretinoína que tem biodisponibilidade aumentada, em que a dita composição está na forma de uma dispersão sólida que compreende isotretinoína e uma matriz farmaceuticamente aceitável. a presente invenção refere-se adicionalmente a um processo para preparar a composição farmacêutica oral da presente invenção.
BR112017025739A 2015-05-29 2015-05-29 composição farmacêutica oral de isotretinoína que tem biodisponibilidade aumentada, processo para preparar a mesma e método de tratamento BR112017025739A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2015/054090 WO2016193779A1 (en) 2015-05-29 2015-05-29 Oral pharmaceutical composition of isotretinoin

Publications (1)

Publication Number Publication Date
BR112017025739A2 true BR112017025739A2 (pt) 2018-08-07

Family

ID=57397385

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017025739A BR112017025739A2 (pt) 2015-05-29 2015-05-29 composição farmacêutica oral de isotretinoína que tem biodisponibilidade aumentada, processo para preparar a mesma e método de tratamento

Country Status (9)

Country Link
US (1) US20160346241A1 (pt)
EP (1) EP3302438A4 (pt)
JP (1) JP2018516262A (pt)
AU (1) AU2015397336A1 (pt)
BR (1) BR112017025739A2 (pt)
CA (1) CA2987517A1 (pt)
MX (1) MX2017015322A (pt)
RU (1) RU2017144222A (pt)
WO (1) WO2016193779A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10517846B2 (en) 2016-05-26 2019-12-31 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions for treating acne
EP3534961A4 (en) 2016-11-02 2020-05-27 Centrexion Therapeutics Corporation STABLE AQUEOUS INJECTABLE CAPSAICIN FORMULATIONS AND MEDICAL USES THEREOF
CN111201015A (zh) 2017-07-20 2020-05-26 中枢疗法公司 使用辣椒素治疗疼痛的方法和组合物
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545977A (en) * 1985-01-11 1985-10-08 G. D. Searle & Co. Compositions and methods for treating severe acne with isotretinoin
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
AU2001289438A1 (en) * 2000-09-22 2002-04-02 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
JP2005507934A (ja) * 2001-10-30 2005-03-24 ネクター セラピューティックス エイエル，コーポレイション レチノイン酸の水溶性ポリマー結合体
PL2200588T3 (pl) * 2007-09-25 2019-09-30 Solubest Ltd. Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania
CA2836228A1 (en) * 2012-12-13 2014-03-06 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
WO2016189481A1 (en) * 2015-05-25 2016-12-01 Sun Pharmaceutical Industries Limited Once daily oral pharmaceutical composition of isotretinoin

Also Published As

Publication number Publication date
US20160346241A1 (en) 2016-12-01
EP3302438A4 (en) 2019-01-09
RU2017144222A (ru) 2019-07-02
CA2987517A1 (en) 2016-12-08
AU2015397336A1 (en) 2017-12-21
WO2016193779A1 (en) 2016-12-08
JP2018516262A (ja) 2018-06-21
MX2017015322A (es) 2018-03-28
RU2017144222A3 (pt) 2019-07-17
EP3302438A1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
CO2017006962A2 (es) Derivados de 2-anilinopirimidina sustituida como moudladores de egfr
CL2014002077A1 (es) Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple.
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
BR112016017996A2 (pt) 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
CL2015001772A1 (es) Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma.
BR112016021282A8 (pt) processos para a preparação de compostos antifúngicos e os referidos compostos
BR112017006342A2 (pt) composto de sal de ácido benzenossulfônico, forma em estado sólido cristalino, composição farmacêutica, produto farmacêutico de combinação, método de tratamento de doenças ou condições, uso de um composto de sal de ácido benzenossulfônico, e, processo para preparação de um composto de sal de ácido benzenossulfônico.
BR112015014176A2 (pt) associação de uma imagem de nuvem de pontos com um desenho de linhas de tubulação e aplicação de dimensões relativas à mesma
BR112017025739A2 (pt) composição farmacêutica oral de isotretinoína que tem biodisponibilidade aumentada, processo para preparar a mesma e método de tratamento
BR112017006779A2 (pt) composição farmacêutica oral de baixa dose seu processo de preparação e método de tratamento
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica
BR112015002493A2 (pt) composto , composição farmacêutica , método para o tratamento do câncer , processo para a preparação de uma composição farmacêutica , conjunto , utilização de um composto e invenção.
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
BR112017025427A2 (pt) composição farmacêutica oral
BR112017014085A2 (pt) processos para a preparação de hemifumarato de tenofovir alafenamida amorfo e uma pré-mistura do mesmo
PE20150721A1 (es) Composicion farmaceutica que comprende gemigliptina y metformina, y metodo para su preparacion
CR20160432A (es) Inhibidores de las vías de señalización de wnt
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
BR112014025972A8 (pt) monocloridratos de anamorelina, composições, processo para preparar monocloridrato de anamorelina, método para produzir uma forma de dosagem farmacêutica e forma de dosagem farmacêutica oral
BR112017028224A2 (pt) composição, e, método para proteger um leitão contra uma doença associada a pestivírus.
BR112019002729A2 (pt) composição farmacêutica sólida e processo para preparar uma composição farmacêutica sólida
BR112019005426A2 (pt) composições de éster de colina de ácido lipoico e métodos para estabilizar em produtos de fármaco farmaceuticamente relevantes

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2594 DE 24-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.